DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xhsf7n/nerve_injury) has announced the addition of the "Nerve Injury - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Nerve Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Injury and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acorda Therapeutics, Inc.
- Calico LLC
- F. Hoffmann-La Roche Ltd.
- Human Stem Cells Institute
- Kolon Life Science, Inc.
- Neuralstem, Inc.
- Neurotune AG
Drug Profiles
- 3K3A-APC
- ACTX-07
- cimaglermin alfa
- CLP-257
- Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders
- KLS-Nst
- NSI-566
- NT-1654
- Small Molecules to Activate NAMPT for Neurological Disorders
- Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury
For more information visit http://www.researchandmarkets.com/research/xhsf7n/nerve_injury
